-
1.发明申请Inhibition of pathogenic agents including alpha6beta1 integrin receptor of alpha6beta4 integrin receptor at a surface 失效包括alpha6beta1整合素受体在表面的病原体包括α6β1整联蛋白受体的抑制公开(公告)号：US20060275256A1
公开(公告)日：2006-12-07
申请号：US11440746
申请日：2006-05-25
IPC分类号： A61K39/395 , A61K38/21 , A61K38/20 , A61K38/19 , C07H21/04 , A61K31/739 , C07K16/28 , C07K14/52 , C07K14/54 , C07K14/56
CPC分类号： C07K14/78 , A61K38/00 , A61K38/1777 , C07K2319/00
摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
摘要翻译： 公开了使用针对致病病原体的疾病的试剂在病原体表面上包含α6β1整联蛋白受体和/或α6β4整联蛋白受体的治疗剂和治疗方法。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已显示结合α6β1整联蛋白受体和α6β4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到可用于破坏或中和病原体的另一种材料的融合或嵌合物质。
-
公开(公告)号：US20050220760A1
公开(公告)日：2005-10-06
申请号：US10817423
申请日：2004-04-02
CPC分类号： C07K14/78 , A61K38/00 , A61K38/1777 , C07K2319/00
摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
摘要翻译： 公开了使用针对致病病原体的疾病的试剂在病原体表面上包含α6β1整联蛋白受体和/或α6β4整联蛋白受体的治疗剂和治疗方法。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已显示结合α6β1整联蛋白受体和α6β4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到可用于破坏或中和病原体的另一种材料的融合或嵌合物质。
-
搜索结果
2 条记录 (耗时 0.01 秒)
